The purpose of this guidance is to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA) or supplemental NDA (21 CFR 314.101(d)) or a biologics license application (BLA) or supplemental BLA (21 CFR 601.2) for a therapeutic biological product regulated by CDER,2 and to underscore the importance of submitting a complete application to minimize the chance of a refuse-to-file (RTF) action by the FDA. In particular, this guidance focuses on the FDA’s policy for refusing to file an NDA under § 314.101(d)(3) when the NDA is incomplete because it does not on its face contain information required under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 314.50
Artigos recentes
- Novo Sistema de Informação para Dispositivos Médicos (SIDM)
- Guide to Using EUDAMED
- Últimas vagas para a formação “Gestão de Alterações aos termos de AIM”
- Vagas esgotadas para a formação sobre AUDITORIAS e INSPEÇÃO em FARMACOVIGILÂNCIA
- EMA offers new Q&A on data monitoring committees
- EMA moves to IRIS for scientific advice questions
- Informação para os titulares de autorização de introdução no mercado: atualização do estado de comercialização
- EMA Guideline : Quality of water for pharmaceutical use